Manganese-enhanced MRI: Comparison of agents in the rat pancreas
Mangafodipir was approved for use as an MRI contrast agent in the late 1990s for liver and pancreas imaging but it was removed from the European market for commercial reasons in 2012. Previously, preliminary work in mice and in diabetic patients showed that Mn2+ ions could be used as a contrast agen...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-12-01
|
Series: | Journal of Magnetic Resonance Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666441020300029 |
id |
doaj-6351a502e722460a86011c10635b6b66 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lucy E Kershaw David ML Lilburn Maurits A. Jansen Andrew R Bond Salamah M Alwahsh Pilar Jimenez-Royo Antonella Napolitano Philip Murphy Alexandra Roberts Rob Janiczek Shareen Forbes Scott IK Semple |
spellingShingle |
Lucy E Kershaw David ML Lilburn Maurits A. Jansen Andrew R Bond Salamah M Alwahsh Pilar Jimenez-Royo Antonella Napolitano Philip Murphy Alexandra Roberts Rob Janiczek Shareen Forbes Scott IK Semple Manganese-enhanced MRI: Comparison of agents in the rat pancreas Journal of Magnetic Resonance Open Manganese Diabetes Pancreas β-cells Pancreatic islets |
author_facet |
Lucy E Kershaw David ML Lilburn Maurits A. Jansen Andrew R Bond Salamah M Alwahsh Pilar Jimenez-Royo Antonella Napolitano Philip Murphy Alexandra Roberts Rob Janiczek Shareen Forbes Scott IK Semple |
author_sort |
Lucy E Kershaw |
title |
Manganese-enhanced MRI: Comparison of agents in the rat pancreas |
title_short |
Manganese-enhanced MRI: Comparison of agents in the rat pancreas |
title_full |
Manganese-enhanced MRI: Comparison of agents in the rat pancreas |
title_fullStr |
Manganese-enhanced MRI: Comparison of agents in the rat pancreas |
title_full_unstemmed |
Manganese-enhanced MRI: Comparison of agents in the rat pancreas |
title_sort |
manganese-enhanced mri: comparison of agents in the rat pancreas |
publisher |
Elsevier |
series |
Journal of Magnetic Resonance Open |
issn |
2666-4410 |
publishDate |
2019-12-01 |
description |
Mangafodipir was approved for use as an MRI contrast agent in the late 1990s for liver and pancreas imaging but it was removed from the European market for commercial reasons in 2012. Previously, preliminary work in mice and in diabetic patients showed that Mn2+ ions could be used as a contrast agent to monitor the function of insulin-producing β-cells by acting as a calcium analogue. Clinical translation of this work was hampered by a lack of available Mn contrast agents, but both mangafodipir and Mn gluconate are currently being used in clinical trials.As a first step towards using Mn in diabetic patients to monitor treatment or disease progression, we imaged the pancreas of healthy rats using mangafodipir, Mn gluconate and Mn chloride (as a control). The hypothesis was that Mn gluconate produces pancreatic enhancement similar to that seen previously with mangafodipir and Mn chloride, with greater enhancement following glucose challenge vs saline challenge. 18 Wistar rats were imaged at 7 T and normalised plateau pancreatic enhancement over baseline was compared for saline vs glucose challenge, calculated from a sigmoid fit to the enhancement curve. For saline vs glucose challenge, mean increases in plateau height ± sd were: 22 ± 18% for Mn chloride, 31 ± 29% for mangafodipir and 41 ± 17% for Mn gluconate. A paired t-test indicated that enhancement was greater for glucose vs saline (p=0.01) and that there was no significant difference in the percentage enhancement between any of the compounds (p>0.2). In conclusion, all three contrast agents produced similar enhancement, with greater plateau height under glucose challenge vs saline challenge. Mangafodipir and Mn gluconate show potential for translation into a clinical study investigating beta cell imaging of the pancreas in type 1 diabetes mellitus and type 2 diabetes. |
topic |
Manganese Diabetes Pancreas β-cells Pancreatic islets |
url |
http://www.sciencedirect.com/science/article/pii/S2666441020300029 |
work_keys_str_mv |
AT lucyekershaw manganeseenhancedmricomparisonofagentsintheratpancreas AT davidmllilburn manganeseenhancedmricomparisonofagentsintheratpancreas AT mauritsajansen manganeseenhancedmricomparisonofagentsintheratpancreas AT andrewrbond manganeseenhancedmricomparisonofagentsintheratpancreas AT salamahmalwahsh manganeseenhancedmricomparisonofagentsintheratpancreas AT pilarjimenezroyo manganeseenhancedmricomparisonofagentsintheratpancreas AT antonellanapolitano manganeseenhancedmricomparisonofagentsintheratpancreas AT philipmurphy manganeseenhancedmricomparisonofagentsintheratpancreas AT alexandraroberts manganeseenhancedmricomparisonofagentsintheratpancreas AT robjaniczek manganeseenhancedmricomparisonofagentsintheratpancreas AT shareenforbes manganeseenhancedmricomparisonofagentsintheratpancreas AT scottiksemple manganeseenhancedmricomparisonofagentsintheratpancreas |
_version_ |
1724216632944885760 |
spelling |
doaj-6351a502e722460a86011c10635b6b662021-03-18T04:42:49ZengElsevierJournal of Magnetic Resonance Open2666-44102019-12-011100002Manganese-enhanced MRI: Comparison of agents in the rat pancreasLucy E Kershaw0David ML Lilburn1Maurits A. Jansen2Andrew R Bond3Salamah M Alwahsh4Pilar Jimenez-Royo5Antonella Napolitano6Philip Murphy7Alexandra Roberts8Rob Janiczek9Shareen Forbes10Scott IK Semple11Edinburgh Imaging, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom; Centre for Inflammation Research, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom; Corresponding author.Edinburgh Imaging, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom; Centre for Inflammation Research, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United KingdomEdinburgh Imaging, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom; BHF/University of Edinburgh Centre for Cardiovascular Science, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United KingdomEndocrinology Unit, BHF/University Centre for Cardiovascular Science, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United KingdomMRC Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU, UKGlaxoSmithKline, Gunnels Wood Road, Stevenage, Herts SG1 2NY, United KingdomGlaxoSmithKline, Gunnels Wood Road, Stevenage, Herts SG1 2NY, United KingdomGlaxoSmithKline, Gunnels Wood Road, Stevenage, Herts SG1 2NY, United KingdomGlaxoSmithKline, Gunnels Wood Road, Stevenage, Herts SG1 2NY, United KingdomGlaxoSmithKline, Gunnels Wood Road, Stevenage, Herts SG1 2NY, United KingdomBHF/University of Edinburgh Centre for Cardiovascular Science, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom; Endocrinology Unit, BHF/University Centre for Cardiovascular Science, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United KingdomEdinburgh Imaging, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom; BHF/University of Edinburgh Centre for Cardiovascular Science, The Queen's Medical Research Centre, Edinburgh Bioquarter, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United KingdomMangafodipir was approved for use as an MRI contrast agent in the late 1990s for liver and pancreas imaging but it was removed from the European market for commercial reasons in 2012. Previously, preliminary work in mice and in diabetic patients showed that Mn2+ ions could be used as a contrast agent to monitor the function of insulin-producing β-cells by acting as a calcium analogue. Clinical translation of this work was hampered by a lack of available Mn contrast agents, but both mangafodipir and Mn gluconate are currently being used in clinical trials.As a first step towards using Mn in diabetic patients to monitor treatment or disease progression, we imaged the pancreas of healthy rats using mangafodipir, Mn gluconate and Mn chloride (as a control). The hypothesis was that Mn gluconate produces pancreatic enhancement similar to that seen previously with mangafodipir and Mn chloride, with greater enhancement following glucose challenge vs saline challenge. 18 Wistar rats were imaged at 7 T and normalised plateau pancreatic enhancement over baseline was compared for saline vs glucose challenge, calculated from a sigmoid fit to the enhancement curve. For saline vs glucose challenge, mean increases in plateau height ± sd were: 22 ± 18% for Mn chloride, 31 ± 29% for mangafodipir and 41 ± 17% for Mn gluconate. A paired t-test indicated that enhancement was greater for glucose vs saline (p=0.01) and that there was no significant difference in the percentage enhancement between any of the compounds (p>0.2). In conclusion, all three contrast agents produced similar enhancement, with greater plateau height under glucose challenge vs saline challenge. Mangafodipir and Mn gluconate show potential for translation into a clinical study investigating beta cell imaging of the pancreas in type 1 diabetes mellitus and type 2 diabetes.http://www.sciencedirect.com/science/article/pii/S2666441020300029ManganeseDiabetesPancreasβ-cellsPancreatic islets |